# BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026
Canonical URL: https://biopharmsignal.com/news/BCRX/biocryst-to-present-new-real-world-evidence-underscoring-the-ongoing-burden-of-pediatric-hereditary-angioedema-at-ispor-2026
Ticker: BCRX
Company: BioCryst Pharmaceuticals
Source: BioCryst Pharmaceuticals
Published: 2026-05-13 11:00 EST
Original Source URL: https://ir.biocryst.com
## Summary

RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new real-world evidence at the 2026 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference taking place in

## Article Body
RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new real-world evidence at the 2026 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference taking place in
## Recent Company News
- 2026-05-27 11:00 EST — [BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting](https://biopharmsignal.com/news/BCRX/biocryst-to-present-new-hae-data-from-orladeyor-berotralstat-and-navenibart-at-the-2026-european-academy-of-allergy-and-clinical-immunology-annual-meeting) — Source: BioCryst Pharmaceuticals
- 2026-05-13 11:00 EST — [BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026](https://biopharmsignal.com/news/BCRX/biocryst-to-present-new-real-world-evidence-underscoring-the-ongoing-burden-of-pediatric-hereditary-angioedema-at-ispor-2026) — Source: BioCryst Pharmaceuticals
- 2026-05-06 11:00 EST — [BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/BCRX/biocryst-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: BioCryst Pharmaceuticals
- 2026-05-05 11:00 EST — [BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: BioCryst Pharmaceuticals
- 2026-05-04 11:00 EST — [BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema](https://biopharmsignal.com/news/BCRX/biocryst-announces-european-licensing-agreement-with-irish-affiliate-of-neopharmed-gentili-for-navenibart-in-hereditary-angioedema) — Source: BioCryst Pharmaceuticals
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)